公开(公告)号：US11807676B2

公开(公告)日：2023-11-07

申请号：US17687732

申请日：2022-03-07

Applicant: UNIVERSITAT ZURICH ,  UNIVERSITAT BASEL

Inventor： Osiris Marroquin Belaunzaran ,  Christoph Renner

IPC: A61K48/00 ,  C07K14/74 ,  A61K39/395 ,  A61P31/22 ,  A61P31/18 ,  A61P31/16 ,  A61P35/00

CPC classification number: C07K14/70539 ,  A61K39/395 ,  A61K48/00 ,  A61P31/16 ,  A61P31/18 ,  A61P31/22 ,  A61P35/00 ,  C07K2319/00 ,  Y02A50/30

Abstract: The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors. Furthermore, the invention relates to the use of MHC-Ia open conformers as immunomodulators, particularly in diseases where the interaction to diverse immunoregulatory receptors such as KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRB2, and PTPRJ modulates an immune response, and in diseases were the negative modulation of Tregs is a therapeutic strategy, e.g. infectious diseases.

公开(公告)号：US11686720B2

公开(公告)日：2023-06-27

申请号：US15770205

申请日：2016-10-24

Applicant: UNIVERSITAT BASEL

Inventor： Marija Plodinec ,  Ellen Obermann ,  Philipp Oertle ,  Christian Räz

IPC: G01N3/42 ,  G01N33/483 ,  G01N33/48 ,  G01N3/00 ,  G01N33/574 ,  G01N3/06 ,  G01Q60/36 ,  G01Q60/24

CPC classification number: G01N33/4833 ,  G01N3/00 ,  G01N3/068 ,  G01N3/42 ,  G01N33/48 ,  G01N33/57415 ,  G01N2203/0089 ,  G01N2203/0286 ,  G01N2291/02827 ,  G01N2800/7028 ,  G01Q60/24 ,  G01Q60/366

Abstract: The invention relates to a method for classifying a tissue sample obtained from mammary carcinoma. The method comprises determining a stiffness value for each of a plurality of points on said tissue sample, resulting in a stiffness distribution, and assigning said sample to a breast cancer subtype and nodal status based on said stiffness distribution.

公开(公告)号：US20220339250A1

公开(公告)日：2022-10-27

申请号：US17849643

申请日：2022-06-26

Applicant: UNIVERSITAT ZURICH ,  UNIVERSITAT BASEL

Inventor： Osiris MARROQUIN BELAUNZARAN ,  Ulf PETRAUSCH ,  Christoph RENNER

IPC: A61K38/17 ,  C07K14/74 ,  A61P37/02 ,  A61P35/00

Abstract: The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.

公开(公告)号：US11279747B2

公开(公告)日：2022-03-22

申请号：US16323902

申请日：2017-08-09

Applicant: UNIVERSITAT ZURICH ,  UNIVERSITAT BASEL

Inventor： Osiris Marroquin Belaunzaran ,  Christoph Renner

IPC: C07K14/74 ,  A61K39/395 ,  A61K48/00 ,  A61P31/22 ,  A61P31/18 ,  A61P31/16 ,  A61P35/00

Abstract: The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors.
Furthermore, the invention relates to the use of MHC-Ia open conformers as immunomodulators, particularly in diseases where the interaction to diverse immunoregulatory receptors such as KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRB2, and PTPRJ modulates an immune response, and in diseases were the negative modulation of Tregs is a therapeutic strategy, e.g. infectious diseases.

公开(公告)号：US20190247466A1

公开(公告)日：2019-08-15

申请号：US16083508

申请日：2017-03-07

Applicant: UNIVERSITAT ZURICH ,  UNIVERSITAT BASEL

Inventor： Osiris MARROQUIN BELAUNZARAN ,  Ulf PETRAUSCH ,  Christoph RENNER

IPC: A61K38/17 ,  A61P37/02 ,  A61P35/00

CPC classification number: A61K38/1774 ,  A61P35/00 ,  A61P37/02 ,  C07K14/70539 ,  C07K2319/30

Abstract: The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents.Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+ T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.

公开(公告)号：US20180369148A1

公开(公告)日：2018-12-27

申请号：US16062122

申请日：2016-12-16

Applicant: UNIVERSITAT BASEL

Inventor： Jorg HUWYLER ,  Maxim PUCHKOV

IPC: A61K9/20 ,  A61K31/485 ,  A61P25/22 ,  A61P25/18 ,  A61P25/04 ,  A61P25/20 ,  A61P3/04

Abstract: The present invention relates to solid oral pharmaceutical dosage forms that provide extended release of active ingredients and have abuse deterrent properties and the methods of making the same. More particularly, the present invention relates to solid oral extended release abuse deterrent dosage forms comprising at least one polycaprolactone (PCL) and at least one gelling agent.

公开(公告)号：US09500670B2

公开(公告)日：2016-11-22

申请号：US14651233

申请日：2013-12-12

Applicant: UNIVERSITAT BASEL

Inventor： Roderick Lim ,  Marija Plodinec ,  Marko Loparic ,  Pascal Oehler ,  Leon Camenzind

IPC: B82Y35/00 ,  G01Q40/00 ,  G01Q30/06 ,  G01Q20/00 ,  G01Q10/06 ,  G01Q10/00

CPC classification number: G01Q20/00 ,  G01Q10/00 ,  G01Q10/065 ,  G01Q30/06

Abstract: The present invention relates to a method for controlling a scanning probe microscope having a probe (2) with a tip (21) for interacting with a sample (4), and a nanoscanner (1) for retaining the sample (4) or the probe (2), comprising the steps of monitoring the extension of the piezo element (1) along a first direction (R) along which the tip (21) is moved towards the sample (4), and adjusting the level of the probe (2) along the first direction (R) by means of an additional actuator (3), when the nanoscanner (1) exhibits an extension below or above a threshold value. The invention further relates to a device (100) for controlling a scanning probe microscope.

Abstract translation: 本发明涉及一种用于控制扫描探针显微镜的方法，所述扫描探针显微镜具有带有用于与样品（4）相互作用的尖端（21）的探针（2）和用于保持样品（4）或探针 （2），包括以下步骤：沿尖端（21）朝向样品（4）移动的第一方向（R）监测压电元件（1）的延伸，并且调节探针（2）的水平 ）当所述纳米扫描仪（1）展现出低于或高于阈值的延伸时，通过附加致动器（3）沿所述第一方向（R）。 本发明还涉及一种用于控制扫描探针显微镜的装置（100）。